ECSP034838A - Inmunoconjugados del anticuerpo cd44 citotoxico - Google Patents

Inmunoconjugados del anticuerpo cd44 citotoxico

Info

Publication number
ECSP034838A
ECSP034838A EC2003004838A ECSP034838A ECSP034838A EC SP034838 A ECSP034838 A EC SP034838A EC 2003004838 A EC2003004838 A EC 2003004838A EC SP034838 A ECSP034838 A EC SP034838A EC SP034838 A ECSP034838 A EC SP034838A
Authority
EC
Ecuador
Prior art keywords
antibody
conjugates
maitansinoid
immunoconjugados
citotoxic
Prior art date
Application number
EC2003004838A
Other languages
English (en)
Spanish (es)
Inventor
Elinborg Ostermann
Guenther Adolf
Erik Patzelt
Marlies Sproll
Karl-Heinz Heider
John J Miglietta
Dongen Augustinus Antonius Van
Original Assignee
Boehringer Ingelheim International Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International Gmbh filed Critical Boehringer Ingelheim International Gmbh
Publication of ECSP034838A publication Critical patent/ECSP034838A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2884—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD44
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
EC2003004838A 2001-05-18 2003-11-10 Inmunoconjugados del anticuerpo cd44 citotoxico ECSP034838A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01112237 2001-05-18

Publications (1)

Publication Number Publication Date
ECSP034838A true ECSP034838A (es) 2003-12-24

Family

ID=33442672

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2003004838A ECSP034838A (es) 2001-05-18 2003-11-10 Inmunoconjugados del anticuerpo cd44 citotoxico

Country Status (18)

Country Link
EP (1) EP1397387A1 (cg-RX-API-DMAC7.html)
JP (1) JP2005504517A (cg-RX-API-DMAC7.html)
CN (1) CN1541226A (cg-RX-API-DMAC7.html)
AR (1) AR036154A1 (cg-RX-API-DMAC7.html)
BR (1) BR0210905A (cg-RX-API-DMAC7.html)
CA (1) CA2443437A1 (cg-RX-API-DMAC7.html)
CZ (1) CZ20033476A3 (cg-RX-API-DMAC7.html)
EA (1) EA200301169A1 (cg-RX-API-DMAC7.html)
EC (1) ECSP034838A (cg-RX-API-DMAC7.html)
EE (1) EE200300569A (cg-RX-API-DMAC7.html)
HU (1) HUP0400030A3 (cg-RX-API-DMAC7.html)
MX (1) MXPA03010523A (cg-RX-API-DMAC7.html)
PE (1) PE20021098A1 (cg-RX-API-DMAC7.html)
PL (1) PL365735A1 (cg-RX-API-DMAC7.html)
SK (1) SK15592003A3 (cg-RX-API-DMAC7.html)
WO (1) WO2002094879A1 (cg-RX-API-DMAC7.html)
YU (1) YU91403A (cg-RX-API-DMAC7.html)
ZA (1) ZA200307365B (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8048416B2 (en) 1999-10-08 2011-11-01 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US20050100542A1 (en) 1999-10-08 2005-05-12 Young David S. Cytotoxicity mediation of cells evidencing surface expression of CD44
US7189397B2 (en) 1999-10-08 2007-03-13 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US7947496B2 (en) 1999-10-08 2011-05-24 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US8071072B2 (en) 1999-10-08 2011-12-06 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US7084257B2 (en) 2001-10-05 2006-08-01 Amgen Inc. Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
CA2556027C (en) * 2004-02-12 2015-11-24 Morphotek, Inc. Monoclonal antibodies that specifically block biological activity of a tumor antigen
EP2322560B1 (en) 2005-03-10 2013-09-04 Morphotek, Inc. Anti-mesothelin antibodies
EP2172487A1 (en) 2005-04-22 2010-04-07 Morphotek Inc. Antibodies with Immune Effector Activity that Internalize in Folate Receptor Alpha-Positive Cells
ES2681195T3 (es) * 2007-06-13 2018-09-12 Zymogenetics, Inc Utilización de la proteína de fusión TACI-Ig, tal como atacicept, para la fabricación de un medicamento para el tratamiento de lupus eritematoso
EP2009028A1 (en) * 2007-06-27 2008-12-31 Monoclonal Antibodies Therapeutics Combination of a conventional anti-cancer treatment with anti-CD44 antibody administration for treating solid tumors
SI2531527T1 (sl) 2010-02-04 2014-07-31 F. Hoffmann-La Roche Ag Monoklonsko protitelo proti CD44 za uporabo pri zdravljenju skvamoznoceličnega karcinoma glave in vratu
CN102337298B (zh) * 2011-08-19 2013-11-06 黄开红 一种输送siRNA的免疫纳米载体及其制备方法和应用
EP2788024A1 (en) 2011-12-06 2014-10-15 F.Hoffmann-La Roche Ag Antibody formulation
WO2017215637A1 (zh) * 2016-06-15 2017-12-21 李翀 一种人子宫内膜癌的标志物、抗体及其应用
CN107556388A (zh) * 2016-06-30 2018-01-09 中国科学院深圳先进技术研究院 抗CD44v6和CD3特异性双靶向抗体、含该双靶向抗体表达盒的微环DNA及应用
JP7859981B2 (ja) * 2020-03-06 2026-05-15 ジーオー セラピューティクス,インコーポレイテッド 抗グリコcd44抗体およびその使用
EP4301782A1 (en) * 2021-03-05 2024-01-10 Go Therapeutics, Inc. Anti-glyco-cd44 antibodies and their uses

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) * 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
EP0438310A1 (en) * 1990-01-19 1991-07-24 Merck & Co. Inc. Method for producing recombinant immunoglobuline
GB9020282D0 (en) * 1990-09-17 1990-10-31 Gorman Scott D Altered antibodies and their preparation
CA2149635A1 (en) * 1992-11-20 1994-06-09 David Tarin Peptide corresponding to cd44 exon 6, antibodies specific for said peptide and use of these antibodies for diagnosis of tumors
UA58482C2 (uk) * 1994-06-08 2003-08-15 Бьорінгер Інгельхайм Інтернаціональ Гмбх Моноклональне антитіло vff-18 проти сd44v6 і його фрагменти
UY24389A1 (es) * 1995-12-06 2001-10-25 Karlsruhe Forschzent Composición farmacéutica para el tratamiento de carcinoma de epitelio plano

Also Published As

Publication number Publication date
SK15592003A3 (sk) 2004-06-08
CN1541226A (zh) 2004-10-27
HUP0400030A2 (hu) 2004-04-28
EP1397387A1 (en) 2004-03-17
EE200300569A (et) 2004-04-15
WO2002094879A1 (en) 2002-11-28
HUP0400030A3 (en) 2006-02-28
CZ20033476A3 (cs) 2004-05-12
AR036154A1 (es) 2004-08-18
YU91403A (sh) 2006-05-25
PE20021098A1 (es) 2003-02-11
BR0210905A (pt) 2004-06-08
EA200301169A1 (ru) 2004-06-24
MXPA03010523A (es) 2004-07-01
ZA200307365B (en) 2004-05-10
CA2443437A1 (en) 2002-11-28
JP2005504517A (ja) 2005-02-17
PL365735A1 (en) 2005-01-10

Similar Documents

Publication Publication Date Title
AR018634A1 (es) Derivados de benzo(b)tiepin-1,1,-dioxido, procedimiento para su preparacion, medicamentos conteniendo estos compuestos, procedimiento para la preparacion de medicamentos y su empleo para la preparacion de medicamentos.
MX9300498A (es) Derivados de n-sulfonil-2-oxo-indol, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
AR012315A1 (es) Derivados de ditiolan y el uso de los mismos en la fabricacion de un medicamento.
ES2012809B3 (es) Derivados del taxol, su preparacion y composiciones farmaceuticas que los contienen.
AR033499A1 (es) Derivado de quinazolina, proceso para su preparacion, composicion farmaceutica que lo comprende y su uso en la fabricacion de medicamentos para usar en la produccion de un efecto antiangeogenico y/o reductor de la permeabilidad vascular en un animal de sangre caliente
ES2054860T5 (es) Derivados de 9-halogeno-(z)-prostaglandinas, procedimiento para su preparacion y su utilizacion como medicamentos.
ECSP066667A (es) Derivados de ciclohexano espirociclicos
ES2071510T3 (es) Derivados de pirrolidina y de tiazolidina, su preparacion y los medicamentos que les contienen.
AR065937A2 (es) Compuesto derivado indazol, composicion farmaceutica que lo comprende y su uso en la fabricacion de medicamentos para modular la actividad de proteina quinasa
ES2176480T3 (es) Derivados acilados de la melatonina y de analogos como medicamentos.
ES2100907T3 (es) Bencimidazoles, medicamentos que contienen estos compuestos y proced imiento para su preparacion.
YU91503A (sh) Citotoksični imunokonjugati sa antitelima specifičnim za cd44
MX9305769A (es) Nuevos derivados de analogos del taxol, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
ECSP034831A (es) Derivados sustituidos de la 2-piridina ciclohexano-1,4-diamina
SV1999000118A (es) Nuevos derivados de pirazol substituidos ref. lea 33188-sv
AR012825A1 (es) Piridinas substituidas como inhibidores selectivos de ciclooxigenasa 2, una composicion farmaceutica que las contiene y su uso para la fabricacion de medicamentos
CO5590895A2 (es) Derivados de sulfonamidas, su preparacion y su aplicacion como medicamentos
IT1173374B (it) Derivati pirido-benzotiazinici ad elevata attivita' antimicrobica
CL2021003594A1 (es) Derivados de 3,6-diamino-piridazin-3-ilo, composiciones farmacéuticas que los contienen y sus usos como agentes proapoptóticos.
ES2115904T3 (es) Derivados amino ramificados del tiazol, sus procedimientos de preparacion y las composiciones farmaceuticas que los contienen.
ES2122637T3 (es) Derivados de tiazolidina, su preparacion y los medicamentos que les contienen.
AR043487A1 (es) Heterociclos fusionados de pirimidina y usos de los mismos
ES2062706T3 (es) Nuevos derivados de amino-metil-piperidina su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
CO5040004A1 (es) 2-4-diamino-1,3,5-triazinas, su preparacion y empleo como herbicidas y fitorreguladores
ES2083625T3 (es) Derivados de n-feniltiourea y uso farmaceutico de los mismos.